Cross sectional analysis of respiratory symptoms in an injection drug user cohort: The impact of obstructive lung disease and HIV

BMC Pulmonary Medicine

Volumn 10, Issue , 2010, Pages

  Drummond, M Bradley ^a   Kirk, Gregory D ^a,b   Ricketts, Erin P ^b   McCormack, Meredith C ^a   Hague, J Christian ^b   McDyer, John F ^a   Mehta, Shruti H ^b   Engels, Eric A ^a,c   Wise, Robert A ^a   Merlo, Christian A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION DRUG USE; MAJOR CLINICAL STUDY; MALE; PHLEGMON; QUESTIONNAIRE; SMOKING; SOCIAL PROBLEM; SYMPTOM; WHEEZING; ABNORMAL RESPIRATORY SOUND; ADDICTION; COHORT ANALYSIS; DRUG USE; HOSPITALIZATION; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; SPIROMETRY; SUBSTANCE ABUSE; UNITED STATES;

ADULT; BALTIMORE; COHORT STUDIES; COUGH; CROSS-SECTIONAL STUDIES; DRUG USERS; DYSPNEA; FEMALE; HIV INFECTIONS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PREVALENCE; RESPIRATORY FUNCTION TESTS; RESPIRATORY SOUNDS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 77951951195     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-10-27     Document Type: Article

References (43)

1. Schoener EP, Hopper JA, Pierre JD. Injection drug use in North America. Infect Dis Clin North Am 2002, 16:535-551. vii..
2. Alcabes P, Friedland G. Injection drug use and human immunodeficiency virus infection. Clin Infect Dis 1995, 20:1467-1479.
3. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health 1998, 88:108-113.
4. Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am 2002, 16:697-712.
5. Gachupin-Garcia A, Selwyn PA, Budner NS. Population-based study of malignancies and HIV infection among injecting drug users in a New York City methadone treatment program, 1985-1991. AIDS 1992, 6:843-848.
6. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000, 30(Suppl 1):S77-84.
7. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998, 93:785-789.
8. Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, Moore RD. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007, 21:2435-2443.
9. Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS 2007, 21:207-213.
10. Kirk GD, Merlo C, P OD, Mehta SH, Galai N, Vlahov D, Samet J, Engels EA. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007, 45:103-110.
11. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006, 130:1326-1333.
12. Overland ES, Nolan AJ, Hopewell PC. Alteration of pulmonary function in intravenous drug abusers. Prevalence, severity, and characterization of gas exchange abnormalities. Am J Med 1980, 68:231-237.
13. Sherman CB, Hudson LD, Pierson DJ. Severe precocious emphysema in intravenous methylphenidate (Ritalin) abusers. Chest 1987, 92:1085-1087.
14. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996, 86:642-654.
15. Des Jarlais DC, Friedman SR. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS 1987, 1:67-76.
16. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep 2009, 57:1-134.
17. CDC HIV/AIDS Surveillance Report, 2006. Vol. 18. Book HIV/AIDS Surveillance Report, 2006, (Editor ed.^ds.) 2008, 18. City: CDC, CDC.
18. Burns DN, Hillman D, Neaton JD, Sherer R, Mitchell T, Capps L, Vallier WG, Thurnherr MD, Gordin FM. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:374-383.
19. Diaz PT, Clanton TL, Pacht ER. Emphysema-like pulmonary disease associated with human immunodeficiency virus infection. Ann Intern Med 1992, 116:124-128.
20. Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Nagaraja HN, Drake J, Clanton TL. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000, 132:369-372.
21. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, Solomon L, Polk BF. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991, 109:75-100.
22. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
23. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187.
24. Gomez FP, Rodriguez-Roisin R. Global initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 2002, 8:81.
25. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978, 118:1-120.
26. Fletcher CM. The clinical diagnosis of pulmonary emphysema; an experimental study. Proc R Soc Med 1952, 45:577-584.
27. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999, 54:581-586.
28. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
29. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med 2007, 101:146-153.
30. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T, Izumi T. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 1999, 116:1632-1637.
31. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002, 121:1434-1440.
32. Enright PL, Kronmal RA, Higgins MW, Schenker MB, Haponik EF. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest 1994, 106:827-834.
33. George MP, Kannass M, Huang L, Sciurba FC, Morris A. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS One 2009, 4:e6328.
34. Diaz PT, Wewers MD, Pacht E, Drake J, Nagaraja HN, Clanton TL. Respiratory symptoms among HIV-seropositive individuals. Chest 2003, 123:1977-1982.
35. Crothers K, Griffith TA, McGinnis KA, Rodriguez-Barradas MC, Leaf DA, Weissman S, Gibert CL, Butt AA, Justice AC. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med 2005, 20:1142-1145.
36. Matsumoto T, Miike T, Nelson RP, Trudeau WL, Lockey RF, Yodoi J. Elevated serum levels of IL-8 in patients with HIV infection. Clin Exp Immunol 1993, 93:149-151.
37. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988, 85:289-291.
38. Rimaniol AC, Zylberberg H, Zavala F, Viard JP. Inflammatory cytokines and inhibitors in HIV infection: correlation between interleukin-1 receptor antagonist and weight loss. AIDS 1996, 10:1349-1356.
39. Denis M, Ghadirian E. Dysregulation of interleukin 8, interleukin 10, and interleukin 12 release by alveolar macrophages from HIV type 1-infected subjects. AIDS Res Hum Retroviruses 1994, 10:1619-1627.
40. Yearsley MM, Diaz PT, Knoell D, Nuovo GJ. Correlation of HIV-1 detection and histology in AIDS-associated emphysema. Diagn Mol Pathol 2005, 14:48-52.
41. Talwar A, Sarkar P, Rosen MJ. Pulmonary arterial hypertension in human immunodeficiency virus infection. Postgrad Med 2009, 121:56-67.
42. Selwyn PA, Feingold AR, Hartel D, Schoenbaum EE, Alderman MH, Klein RS, Friedland GH. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988, 2:267-272.
43. Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, Rosen MJ, Kvale PA, Mangura BT, Reichman LB, Hopewell PC. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997, 155:72-80.